All In Biotech

Drug Trial Radar · NCT01194245

Safety/Efficacy Study of Subcutaneously Injected Prandial Insulins Compared to Insulin Lispro Alone in Participants With Type 1 Diabetes Mellitus

A Phase II, Randomized, Double Blind, 2-Way Crossover Safety and Efficacy Study of Subcutaneously Injected Prandial Insulins: Lispro-PH20 or Aspart-PH20 Compared to Insulin Lispro (Humalog®) in Patients With Type 1 Diabetes

Last checked: Nov 20, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 135 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

135

Actual

Start

Aug 2010

Primary completion

Aug 2011

Study completion Aug 2011

Sponsor

Lead sponsor
Halozyme TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to compare Humalog (Insulin lispro)-recombinant human hyaluronidase (rHuPH20) or Novolog (Insulin aspart)-rHuPH20 to Humalog (Insulin lispro) for the treatment of Type 1 Diabetes Mellitus (T1DM) in basal-bolus therapy.

Conditions

  • Diabetes Mellitus, Type 1

Interventions

  • Insulin lisproDrug

  • recombinant human hyaluronidase PH20Drug

  • Insulin aspartDrug

  • Insulin glulisineDrug

  • Insulin glargineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Glycosylated Hemoglobin A1C (HbA1c) at the End of Each Treatment PeriodTime frame: Baseline, Week 12 and Week 24

Locations

19 sites in 1 country. Site status is shown where the registry gives one.

  • AMCR Institute, Inc.

    Escondido, California

  • Scripps Whittier Diabetes Institute

    La Jolla, California

  • Mills-Peninsula Health Services

    San Mateo, California

  • Barbara Davis Center for Childhood Diabetes

    Aurora, Colorado

  • Center for Diabetes and Endocrine Care

    Hollywood, Florida

  • Diabetes Research Institute

    Miami, Florida

  • Rocky Mountain Diabetes and Osteoporosis Center

    Idaho Falls, Idaho

  • Mid-America Diabetes Associates

    Wichita, Kansas

  • Tulane University Health Sciences Center

    New Orleans, Louisiana

  • Medstar Research Institute

    Hyattsville, Maryland

  • Henry Ford Health System

    Detroit, Michigan

  • International Diabetes Center

    Minneapolis, Minnesota

  • Mercury Street Medical

    Butte, Montana

  • Desert Endocrinology

    Henderson, Nevada

  • UT Southwestern Medical Center at Dallas

    Dallas, Texas

  • Texas Diabetes and Endocrinology

    Round Rock, Texas

  • Cetero Research-San Antonio

    San Antonio, Texas

  • West Olympia Internal Medicine

    Olympia, Washington

  • University of Washington School of Medicine

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.